Alinia

Alinia is a brand name of nitazoxanide, approved by the FDA in the following formulation(s):

ALINIA (nitazoxanide - for suspension; oral)

• 
  Manufacturer: ROMARK
  
  Approval date: November 22, 2002
  
  Strength(s): 100MG/5ML ^[RLD]

ALINIA (nitazoxanide - tablet; oral)

• 
  Manufacturer: ROMARK
  
  Approval date: July 21, 2004
  
  Strength(s): 500MG ^[RLD]

Has a generic version of Alinia been approved?

No. There is currently no therapeutically equivalent version of Alinia available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Alinia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Composition and galenic formulation suitable for combatting affections of the lower abdomen
  Patent 5,387,598
  Issued: February 7, 1995
  Inventor(s): Rossignol; Jean-Francois
  The present invention relates to a composition and a galenic formulation suitable for combatting affections of the lower abdomen, for example intestinal conditions such as diarrhea, said composition or formulation containing: (a) an effective amount of a compound of formula I ##STR1## (b) at least one wetting agent, and preferably (c) a starch derivative.
  
  Patent expiration dates:
  
  
  • February 7, 2012
    
    ✓ 
    Patent use: METHOD OF TREATING DIARRHEA
    ✓ 
    Drug product
  
  
  
  • February 7, 2012
    
    ✓ 
    Patent use: METHOD OF TREATING DIARRHEA
  
  



• 
  Benzamide derivatives
  Patent 5,578,621
  Issued: November 26, 1996
  Inventor(s): Rossignol; Jean-Francois
  The present invention relates to a new compound of formula I ##STR1## with one of the symbols R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 representing OH, whereas the remaining symbols represent H; to a pharmaceutical composition containing the said compound, and to the use of said compound as anti-parasital, anti-bacterial, anti-fungal agent. The Prior Art Nitrothiazole compound PH 5776 (2-(acetolyloxy)-N-(5-nitro 2-thiazolyl) benzamide) is a compound of formula II ##STR2## in which R.sub.1 =O--COCH3 R.sub.2 =R.sub.3 =R.sub.4 =R.sub.5 =H The preparation and uses of this compound are disclosed in U.S. Pat. No. 3,950,351, as well as in publication made by Applicant. In U.S. Pat. No. 3,950,351, the compound of formula II is prepared by reacting ##STR3## This reaction is not suitable for the preparation of pure compound of formula I ##STR4## in which one of the symbols R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 represent OH, whereas the remaining symbols represent H. Moreover, contrary to what could be expected from the prior art, i.e. that the presence of an acyloxy group was necessary for rendering the compound active and efficient against bacteria, parasites, . . . , it has now been found that the compound of formula I ##STR5## with one of the symbols R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 representing OH, whereas the remaining symbols represent H; had an excellent efficiency against parasites, bacteria, fungus although it does not contain an acyloxy group. The compound of formula I had a substantially immediate action against parasite, fungus, bacteria.
  
  Patent expiration dates:
  
  
  • November 26, 2013
    
    ✓ 
    Patent use: METHOD OF TREATING PARASITIC INFECTIONS
    ✓ 
    Drug product
  
  
  
  • September 8, 2014
    
    ✓ 
    Patent use: METHOD OF TREATING PARASITIC INFECTIONS
  
  



• 
  Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
  Patent 5,965,590
  Issued: October 12, 1999
  Inventor(s): Rossignol; Jean-Fran.cedilla.ois
  Methods for treatment of Cryptosporidium parvum, Isospora belli, Enterocytzoon bieneusi, Encephalitozoon intestinalis, Mycobacterium tuberculosis, Mycobacterium avium intracellulare, Pneumocystis carinii, and Toxoplasma gondii, the methods comprising the administration of a pharmaceutical composition containing as active agent at least one compound selected the group consisting of a compound of formula I: ##STR1## and a compound of formula II: ##STR2##
  
  Patent expiration dates:
  
  
  • July 3, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
  
  



• 
  Pharmaceutical compositions of tizoxanide and nitazoxanide
  Patent 5,968,961
  Issued: October 19, 1999
  Inventor(s): Rossignol; Jean-Fran.cedilla.ois
  Assignee(s): Romark Laboratories, L.C.
  The present invention relates to a pharmaceutical composition containing as active agent, solid particles of a compound selected from the group consisting of: compound of formula I ##STR1## and mixtures thereof, said particles having a particle size smaller than 200 .mu.m, the mean particle size of the said active solid particles being greater than 10 .mu.m. It also relates to a pharmaceutical composition which contains at least one pharmaceutically acceptable acid.
  
  Patent expiration dates:
  
  
  • May 7, 2017
    
    ✓ 
    Drug product
  
  
  
  • May 7, 2017
    
  
  



• 
  2-(hydroxy)-N-(5-nitro-2-thiazolyl) benzamide
  Patent 6,020,353
  Issued: February 1, 2000
  Inventor(s): Rossignol; Jean-Francois
  Assignee(s): Romark Laboratories, L.C.
  The present invention relates to a pharmaceutical composition containing a compound of formula I ##STR1## with one of the symbols R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 representing OH, whereas the remaining symbols represent H as antiviral agent.
  
  Patent expiration dates:
  
  
  • September 18, 2014
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 8, 2014
    
  
  



• 
  Acid stabilized pharmaceutical compositions of tizoxanide and nitazoxanide
  Patent 6,117,894
  Issued: September 12, 2000
  Inventor(s): Rossignol; Jean-Fran.cedilla.ois
  Assignee(s): Romark Laboratories, L.C.
  The present invention relates to a pharmaceutical composition containing as active agent, solid particles of a compound selected from the group consisting of: compound of formula I: ##STR1## compound of formula II: ##STR2## and mixtures thereof. said particles having a particle size smaller than 200 .mu.m, the mean particle size of the said active solid particles being greater than 10 .mu.m. It also relates to a pharmaceutical composition which contains at least one pharmaceutically acceptable acid.
  
  Patent expiration dates:
  
  
  • May 7, 2017
    
  
  

See also...

• Alinia Consumer Information (Wolters Kluwer)
• Alinia Suspension Consumer Information (Wolters Kluwer)
• Alinia Consumer Information (Cerner Multum)
• Alinia Advanced Consumer Information (Micromedex)
• Alinia AHFS DI Monographs (ASHP)
• Nitazoxanide Consumer Information (Wolters Kluwer)
• Nitazoxanide Suspension Consumer Information (Wolters Kluwer)
• Nitazoxanide Consumer Information (Cerner Multum)
• Nitazoxanide Advanced Consumer Information (Micromedex)
• Nitazoxanide AHFS DI Monographs (ASHP)